Connection

SUSAN HILSENBECK to Gene Expression Regulation, Neoplastic

This is a "connection" page, showing publications SUSAN HILSENBECK has written about Gene Expression Regulation, Neoplastic.
  1. Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst. 1999 Mar 03; 91(5):453-9.
    View in: PubMed
    Score: 0.087
  2. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):E6600-E6609.
    View in: PubMed
    Score: 0.073
  3. The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression. Oncotarget. 2016 Mar 15; 7(11):13106-21.
    View in: PubMed
    Score: 0.070
  4. Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nat Commun. 2014 Aug 07; 5:4577.
    View in: PubMed
    Score: 0.063
  5. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types. J Pathol. 2014 Apr; 232(5):522-33.
    View in: PubMed
    Score: 0.061
  6. Pttg1/securin is required for the branching morphogenesis of the mammary gland and suppresses mammary tumorigenesis. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):1008-13.
    View in: PubMed
    Score: 0.061
  7. Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells. J Pathol. 2014 Jan; 232(1):75-86.
    View in: PubMed
    Score: 0.060
  8. Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence. Breast Cancer Res Treat. 2012 Nov; 136(1):253-65.
    View in: PubMed
    Score: 0.055
  9. Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat. 2012 Feb; 132(1):61-73.
    View in: PubMed
    Score: 0.050
  10. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009 Aug 18; 106(33):13820-5.
    View in: PubMed
    Score: 0.045
  11. Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer. Clin Cancer Res. 2007 Jun 01; 13(11):3235-43.
    View in: PubMed
    Score: 0.038
  12. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat. 2008 Mar; 108(2):233-40.
    View in: PubMed
    Score: 0.038
  13. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006 Oct 01; 24(28):4611-9.
    View in: PubMed
    Score: 0.037
  14. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat. 2006 Feb; 95(3):229-33.
    View in: PubMed
    Score: 0.035
  15. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003 Aug 02; 362(9381):362-9.
    View in: PubMed
    Score: 0.029
  16. Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer. Clin Cancer Res. 2021 05 01; 27(9):2648-2662.
    View in: PubMed
    Score: 0.025
  17. Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021 02; 40(5):997-1011.
    View in: PubMed
    Score: 0.024
  18. Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat. 2018 02; 167(3):731-740.
    View in: PubMed
    Score: 0.020
  19. Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Res Treat. 2016 08; 158(3):441-54.
    View in: PubMed
    Score: 0.018
  20. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 1995 May 17; 87(10):746-50.
    View in: PubMed
    Score: 0.017
  21. Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer. Cancer Discov. 2015 May; 5(5):520-33.
    View in: PubMed
    Score: 0.016
  22. Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6101-11.
    View in: PubMed
    Score: 0.015
  23. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 2012 Jan 20; 335(6066):348-53.
    View in: PubMed
    Score: 0.013
  24. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2778-83.
    View in: PubMed
    Score: 0.013
  25. Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res. 2011 Jun 15; 17(12):4177-86.
    View in: PubMed
    Score: 0.012
  26. Loss of Rho GDIa and resistance to tamoxifen via effects on estrogen receptor a. J Natl Cancer Inst. 2011 Apr 06; 103(7):538-52.
    View in: PubMed
    Score: 0.012
  27. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell. 2011 Mar 04; 144(5):703-18.
    View in: PubMed
    Score: 0.012
  28. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res. 2011 Apr 15; 17(8):2314-27.
    View in: PubMed
    Score: 0.012
  29. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res. 2011 Mar 15; 17(6):1351-61.
    View in: PubMed
    Score: 0.012
  30. Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis. Neoplasia. 2010 Sep; 12(9):718-26.
    View in: PubMed
    Score: 0.012
  31. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010; 12(3):R40.
    View in: PubMed
    Score: 0.012
  32. Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. Cancer Res. 2010 Jun 15; 70(12):4868-79.
    View in: PubMed
    Score: 0.012
  33. Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma. J Hematol Oncol. 2009 Nov 12; 2:47.
    View in: PubMed
    Score: 0.011
  34. Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst. 2009 Jan 21; 101(2):107-13.
    View in: PubMed
    Score: 0.011
  35. Gene expression in Barrett's esophagus: laser capture versus whole tissue. Scand J Gastroenterol. 2009; 44(7):787-95.
    View in: PubMed
    Score: 0.011
  36. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol. 2008 Sep 01; 26(25):4078-85.
    View in: PubMed
    Score: 0.010
  37. Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo). Breast Cancer Res Treat. 2009 Jun; 115(3):505-21.
    View in: PubMed
    Score: 0.010
  38. Wnt-1 is dominant over neu in specifying mammary tumor expression profiles. Technol Cancer Res Treat. 2006 Dec; 5(6):565-71.
    View in: PubMed
    Score: 0.009
  39. Genomic approaches in the management and treatment of breast cancer. Br J Cancer. 2005 Feb 28; 92(4):618-24.
    View in: PubMed
    Score: 0.008
  40. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2003 Dec 17; 95(24):1825-33.
    View in: PubMed
    Score: 0.008
  41. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):353-61.
    View in: PubMed
    Score: 0.007
  42. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol. 1999 May; 13(5):787-96.
    View in: PubMed
    Score: 0.005
  43. Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol. 1996 Nov; 59(3-4):251-60.
    View in: PubMed
    Score: 0.005
  44. Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst. 1996 May 01; 88(9):601-6.
    View in: PubMed
    Score: 0.004
  45. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst. 1992 Oct 07; 84(19):1486-91.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.